chiral center

chiral center

[′kī·rəl ′sen·tər]
(organic chemistry)
An atom in a molecule that is attached to four different groups.
References in periodicals archive ?
WaVe, which aims to control the chirality of nucleic acid therapeutics, will initially focus on oligonucleotides nucleic acid strings in which each phosphorothioate modification introduces a new chiral center.
Therefore, the phosphorus atom can act as a chiral center unlike a nitrogen atom.
Many chemical compounds used in the formulation of drugs have one or a few chiral centers.
In order to provide the cyanohydrins, first sulfonic is produced which is a sediment and then by adding potassium cyanide to the sulfonic compound, the nitrile group is replaced and the compound of 4-t-butyl-2-(Npiperidinomethyl)cyanocyclohexane is obtained which had active optical chiral centers and is a new analog of active optical cyanohydrin family.
The statement required all drugs with chiral centers to be studied with respect to their left and right enantiomers, or stereoisomers.
Kemin Pharma discovered molecule KPE02003002, a synthetic derivative of a phytochemical with several chiral centers, in October 2002, through a collaborative effort with the National Institutes of Health in Bethesda, Maryland, and the Rega Institute for Medical Research in Leuven, Belgium.
However, the use of chiral secondary alcohols leads to polymers with chiral centers incorporated into main chain.
Like the Delta technology, which remains the basis for oral inhibitors of tryptase under preclinical study by Bayer AG, the new scaffold design paradigm yields inhibitors that are non-peptide, not dependent on chiral centers for activity, and have low molecular weights.
Sas says, "Our research is focused on complete, novel molecules with three dimensional structures, several chiral centers and new modes of action.
Carbohydrates provide a means to achieve multiple contiguous chiral centers that can be chemically manipulated to form the desired drug intermediate.
Being offered commercially for the first time -- Novel, generated using Synthon's proprietary technologies -- Functionally rich and structurally complex, many with multiple chiral centers -- Ready or nearly ready for drug screening or lead development -- Targeted to discovery efforts across a large diversity of drug types